MedPath

Prednisone

Generic Name
Prednisone
Brand Names
Deltasone, Rayos, Winpred
Drug Type
Small Molecule
Chemical Formula
C21H26O5
CAS Number
53-03-2
Unique Ingredient Identifier
VB0R961HZT
Background

A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication

Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions
Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
Associated Therapies
Palliative Treatment
Clinical Trials
Related News

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Phase 1
Completed
Conditions
Cancer
Castrate-Resistant Prostate Cancer
Mestastatic Prostate Cancer
Prostate Cancer
Interventions
Drug: AMG 102
Drug: Placebo
Drug: Mitoxantrone
Drug: Prednisone
First Posted Date
2008-10-10
Last Posted Date
2014-03-10
Lead Sponsor
Amgen
Target Recruit Count
162
Registration Number
NCT00770848

S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Phase 2
Completed
Conditions
Lymphoma
Interventions
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin
Drug: prednisone
Drug: vincristine
Radiation: tositumomab
First Posted Date
2008-10-09
Last Posted Date
2019-08-28
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
87
Registration Number
NCT00770224
Locations
🇺🇸

Doctors Hospital at Ohio Health, Columbus, Ohio, United States

🇺🇸

CCOP - Columbus, Columbus, Ohio, United States

🇺🇸

Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States

and more 111 locations

Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

First Posted Date
2008-10-02
Last Posted Date
2009-07-08
Lead Sponsor
University Hospital, Motol
Target Recruit Count
4000
Registration Number
NCT00764907
Locations
🇨🇿

University Hospital Motol, Prague, Czech Republic

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer

Phase 3
Completed
Conditions
Prostatic Neoplasms
Interventions
Drug: Placebo
Drug: Dasatinib
Drug: Docetaxel
Drug: Prednisone
First Posted Date
2008-09-01
Last Posted Date
2016-10-17
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1930
Registration Number
NCT00744497
Locations
🇺🇸

Maine Center For Cancer Medicine, Scarborough, Maine, United States

🇺🇸

Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States

🇺🇸

Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States

and more 40 locations

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Early Phase 1
Terminated
Conditions
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Stage I Adult Diffuse Large Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma
Interventions
Biological: oblimersen sodium
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Procedure: biopsy
Genetic: microarray analysis
Other: immunohistochemistry staining method
Genetic: gene expression analysis
Genetic: cytogenetic analysis
First Posted Date
2008-08-15
Last Posted Date
2023-10-24
Lead Sponsor
University of Nebraska
Target Recruit Count
37
Registration Number
NCT00736450
Locations
🇺🇸

Saint Francis Medical Center, Grand Island, Nebraska, United States

🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Bortezomib With Melphalan and Prednisone for Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Bortezomib
Drug: Melphalan
Drug: Prednisone
First Posted Date
2008-08-14
Last Posted Date
2023-11-07
Lead Sponsor
Duke University
Target Recruit Count
45
Registration Number
NCT00734149
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Phase 2
Completed
Conditions
Lymphoma
Interventions
Biological: pegfilgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
First Posted Date
2008-08-01
Last Posted Date
2021-07-07
Lead Sponsor
Universität des Saarlandes
Target Recruit Count
109
Registration Number
NCT00726700

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2
Completed
Conditions
Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions
Drug: Asparaginase
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dasatinib
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Drug: Etoposide
Biological: Filgrastim
Drug: Hydrocortisone Sodium Succinate
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Methylprednisolone
Drug: Pegaspargase
Drug: Prednisone
Radiation: Radiation Therapy
Drug: Vincristine Sulfate
First Posted Date
2008-07-22
Last Posted Date
2020-04-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
63
Registration Number
NCT00720109
Locations
🇺🇸

New York Medical College, Valhalla, New York, United States

🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Valley Children's Hospital, Madera, California, United States

and more 131 locations

Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation

Phase 4
Completed
Conditions
Kidney Transplantation
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Interventions
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Methylprednisolone or equivalent
Drug: Prednisone
First Posted Date
2008-07-17
Last Posted Date
2009-04-15
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
50
Registration Number
NCT00717379

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Phase 2
Active, not recruiting
Conditions
Multiple Sclerosis Transplant
Chronic Inflammatory Demyelinating Polyneuropathy
Myasthenia Gravis
Rasmussen Subacute Encephalitis
Neurologic Autoimmune Disease
CIDP Transplant
Central Nervous System Vasculitis
Autoimmune Disease
Autologous Transplant Autoimmune
MS Stem Cell Transplant
Interventions
Biological: Anti-Thymocyte Globulin
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Prednisone
Procedure: Syngeneic Bone Marrow Transplantation
First Posted Date
2008-07-16
Last Posted Date
2024-07-18
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
53
Registration Number
NCT00716066
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

🇺🇸

Swedish Medical Center-First Hill, Seattle, Washington, United States

🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy